Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review
Despite decades of progress in the treatment of head and neck cancer, recurrence and second primary cancers continue to occur. The management of non-metastatic, locoregionally recurrent or second primary cancers is a complex multidisciplinary challenge that often occurs without guidance from robust clinical trials. In 2023, the NRG Oncology cooperative group created the Recurrent and Metastatic Working Group with the express directive to investigate how resources could optimally address the key questions for the recurrent and metastatic populations. Here, we present our view of the state of the science and present considerations for future investigations.
Authors
- Sharon A. Spencer
- Dwight E. Heron (ORCID: https://orcid.org/0000-0001-6282-1806)
- Neal S. Akhave (ORCID: https://orcid.org/0000-0002-1291-0218)
- Anna Spreafico (ORCID: https://orcid.org/0000-0002-3034-3042)
- Jung Julie Kang (ORCID: https://orcid.org/0000-0001-9773-5481)
- Nabil Saba
- Steven S. Chang
- Shauna R Campbell
- Glenn J Hanna
- Sue S Yom
- Matthew C Ward
Institutions
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Emory University (US)
- Henry Ford Health System (US)
- University of California, San Francisco (US)
- Princess Margaret Cancer Centre (CA)
- University of Alabama at Birmingham (US)
- Yale University (US)
- Piedmont Cancer Institute (US)
- Levine Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Bon Secours Mercy Health (US)
- Southeast Radiation Oncology Group (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1093/jnci/djag025
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00